TORBAC

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory Only

Abbreviated Prescribing information for TORBAC [Piperacillin and Tazobactam Injection] [Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: Piperacillin sodium exerts its bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria. Tazobactam sodium is a β -lactamase inhibitor of the Richmond-Sykes class III penicillinases and cephalosporinases. Tazobactam does not induce chromosomally-mediated β -lactamases at tazobactam concentration achieved with the recommended dosage regimen.

INDICATION: In the treatment of lower RTI/UTI/intra abdominal infections, skin and skin structure infections, bacterial septicemia polymicrobic infection

DOSAGE AND ADMINISTRATION: Piperacillin/tazobactam should be administered by intravenous infusion over 30 minutes. The usual total daily dose of Piperacillin/tazobactam for adults is 3.375 g every six hours totaling 13.5 g (12 g piperacillin sodium/1.5 g tazobactam sodium). Dosage for renal insufficient patient is available in full prescribing information. **CONTRAINDICATION**: Torbac is contraindicated in patients with a history of allergic reactions to any of the penicillins, cephalosporins, or β -lactamase inhibitors.

WARNINGS & PRECAUTIONS: Hypersensitivity reactions/Anaphylactic reactions; Pseudomembranous colitis; Abnormalities of coagulation tests; renal failure; Convulsion; hypokalemia.

DRUG INTERACTIONS: Interacts with aminoglycoside; probenecid; vancomycine; heparin; vecuronium; methotrexate; false-positive reaction for glucose in the urine.

ADVERSE REACTIONS: Diarrhea, constipation, nausea, vomiting, dyspepsia, stool changes, abdominal pain, melena, flatulence, hemorrhage, gastritis, hiccough, ulcerative stomatitis, tremor, convulsions, vertigo, dizziness, headache, insomnia, agitation, anxiety, confusion, hallucination, depression, hypertension chest pain, edema, tachycardia, supraventricular and ventricular; bradycardia; arrhythmia, including atrial fibrillation, ventricular fibrillation, cardiac arrest, cardiac failure, circulatory failure, myocardial infarction, rash, pruritus, genital pruritus, diaphoresis, dyspnoea pharyngitis, pulmonary edema, bronchospasm, coughing, rhinitis, tinnitus, fever, rigors, back pain, malaise, hypotension, ileus, syncope, anaphylaxis, hypoglycemia, thirst, pain, myalgia, arthralgia, mesenteric embolism, purpura, epistaxis, pulmonary embolism, moniliasis, leukorrhea, vaginitis, taste perversion, dysuria, oliguria, hematuria, incontinence, photophobia, flushing, thrombophlebitis, injection site reactions, inflammation, pain, phlebitis, superinfection, colitis, Serious skin reactions (SJS, TEN, erythema multiforme), hypersensitivity reactions/anaphylactic reactions, hemolytic anemia, anemia, thrombocytosis, agranulocytosis, pancytopenia, hepatitis, cholestatic jaundice, interstitial nephritis and renal failure.

MARKETED BY:



TORRENT PHARMACEUTICALS LTD.
Torrent House, Off Ashram Road,
Ahmedabad-380 009, INDIA
IN/TORBAC/Mar-2016/02/AbPI
(Additional information is available on request)